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during a single short phase of rapid ventricular pacing. At
the same time, we also perform continuous contrast
injection at the level of the aortic root until the prosthesis
has been at least half deployed. We have also found that
placing a guidewire in left main or right coronary artery
(Figure 1, A) has occasionally been invaluable (3 cases in
our series) in providing us with a landmark for valve
deployment. This has been particularly useful in cases in
which severe aortic regurgitation precluded us from obtain-
ing a satisfactory root angiogram and/or we had difficulties
in obtaining good views of the annulus using TEE.
Other Technical Considerations
First, the surgical details of the bioprosthesis such as the
valve type and size and method of implantation should be
obtained because they are of paramount importance for rea-
sons we have highlighted.
Second, it is essential to rule out infective endocarditis in
any patient presenting with aortic regurgitation in the
setting of a previously placed stentless aortic valve. It
should not be assumed that the cause of the regurgitation
is primary leaflet degeneration.
Third, we do not routinely perform balloon aortic valvu-
loplasty of the degenerated valve before insertion of the
prosthesis unless the possibility of coronary obstruction is
a very great.
Finally, we believe that the surgical approach for access
should be highly individualized after a thorough review of
the preoperative clinical examination and radiographic
investigation (which includes a full computed tomography
aortogram at our center) findings. In the present series, we
performed the procedure using either a transfemoral or
TA approach. However, transaortic access has also been
used for the VIV procedure.21
CONCLUSIONS
We have demonstrated that the TAVI procedure after
previous stentless aortic valve replacement and that the
valve-in-stentless-valve concept is technically feasible and
safe using a balloon expandable SAPIEN THV. The early
results showed improvement in hemodynamics and
symptom amelioration. Larger studies with longer follow-
up are needed to confirm our results.
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Dr A. Pieter Kappetein (Rotterdam, The Netherlands).
Dr Bapat, congratulations on a great report, and again, it is another
excellent contribution from your group for a very complex patient
population.ery c September 2014
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DThe valve that you implanted actually concerns a variety of bio-
prostheses, 6 homografts, 1 Toronto valve, 1 Freestyle valve, 1
O’Brien valve, and 1 Pericarbon valve, and the mean age of those
patients was 73 years. The mean interval from the previous aortic
valve procedure to the implantation of the bioprosthesis or homo-
graft was 14 years, but it concerns a wide range, from 7 years to 27
years. The groups were rather small; thus, I assume you could not
determine a difference between the homografts and xenografts, but
perhaps you could.
Now that VIV procedures are possible, we will see much larger
series of patients with a failing bioprosthesis. If you ask the
average surgeon how many failing bioprostheses they operate on
per year, they will probably say 1 or 2 or 3, depending on the
size of their practice. Last year at EuroPCR, a series was presented
of 450 patients with a failing bioprosthesis, and the mean interval
between implantation of the bioprosthesis and the VIV procedure
was only 9 years. If we study our surgical data, we often see series
with a follow-up period of 20 years and 95% freedom from
reoperation.
So, the question is, what is the reason that we have always
believed that bioprosthetic valves can last 20 years and that
now we actually see large series of patients undergoing a VIV pro-
cedure at a relatively low average age, as you pointed out, 73 years,
but also, that the interval between implantation of the bioprosthesis
and the VIV procedure is not as long as 20 years? Do you think it is
justified, to lower the age at which we implant a bioprosthesis now
that we have the possibility of a VIV procedure?
My last question, do you think that one of the other transcatheter
prostheses, for example a self-expandable valve, might have an
advantage, with a lower risk of coronary obstruction?
Thank you very much again for an excellent presentation.
Dr Bapat. Thank you very much, Dr Kappetein, for your excel-
lent questions.
I think my view is that the reason we are seeing early failure
rates or less durability data in terms of duration is because we
are implanting them in younger patients. I think the series that
showed that the durability of the valves would be 20 years or so
was more historical in which the implantation age for a bio-
prosthesis was 70 plus years.
Today, in most of my practice, I rarely implant a mechanical
valve because even a patient of 50 years requests a tissue valve.
That might explain why we are seeing patients returning slightly
earlier than in the past.
Dr Kappetein. If I could interrupt. If one implants a bio-
prosthesis in a 50-year-old patient, and the mean follow-up for
freedom from reoperation is 15 years, one will need to do a VIV
procedure in a 65-year-old patient. For the transcatheter heart
valves, we do not know the durability in a 65-year-old patient,
and, if the valve lasts, for example, 10 years, one will have a
75-year-old patient in whom you need to perform a valve in a valve
in a valve procedure.
Dr Bapat. I think that is a very good question, and I tend to
match, or my group tends to match, the life expectancy of the pa-
tient to the treatment. My view regarding such patients, the specific
example you gave, would be to reoperate in the patient at 65 years
and then perform a VIVat age 75 or 80 years when he comes, if he
survives to that age, rather than perform a VIV procedure at 65
years and then reoperate when he is 80 years old. However if hisThe Journal of Thoracic and Calife expectancy is shorter because of comorbidities, I think it would
be a reasonable to perform a VIV procedure at age 65 years.
So, I think we need to match the patient’s survival to the type of
treatment we have, and that has been our view at present.
Dr Kappetein. Right.
Dr Bapat. Regarding your third question, which is other de-
vices, yes, a nitinol platform or valves such as the CoreValve
and Portico would definitely have some advantage because they
are self expandable and hence have been favored for scentless
valves.
However, I think positioning a nitinol self-expanding valve be-
comes very tricky because these are longer devices. Also, with
aortic regurgitation, you might not achieve accurate landing in
contrast to a balloon expandable valve, because most balloon
expandable valves are implanted under pacing.
The main reason we presented our report was because of the
fear that a balloon expandable valve needs a lot of anchor, such
as calcium, and might not be suitable for stentless valves at all.
However, I think the fibrosis and suture material provides enough
anchor to implant these valves.
DrKappetein. Thank you verymuch. Do you think that most of
our knowledge of the durability of bioprosthesis is based on reop-
eration-free data and not freedom from valve failure, which are 2
distinct entities.
My impression has been that we see more patients with a failing
bioprosthesis because we have the possibility of a VIV with trans-
catheter heart valve implantation. We might have overestimated
the durability of our bioprosthetic valves.
Dr Bapat. I think I completely agree with you.
Dr Kappetein. Okay. Thank you very much.
Dr Danny Dvir (Vancouver, British Columbia, Canada). Yes.
Dr Kappetein, we were very surprised in the global registry to
see that the median interval to failure between surgery and the
VIV procedure was only 9 years. We were really in shock when
we saw that finding.
The stentless valves do fail, just as you showed, Dr Bapat, really
longer than the stented, 12 to 13 years versus 8 to 9 years.
However, I must say that when we are talking about decreasing
the cutoff age between implantation of a mechanical valve to
bioprosthetic valve, thinking of performing a VIV procedure in
the future, we must understand that some limitations exist to the
VIV field. We have the left main obstruction, the malpositioning,
and, probably the most problematic, the elevated postprocedure
gradients.
So when we are talking about implantation of a bioprosthetic
valve, thinking of performing a VIV procedure in the future, we
should understand that the surgical procedure has a great amount
of impact and influence on the success of performing VIV in the
future. The surgical valve size has a great amount of impact.
The position of the coronaries, the relationship between the surgi-
cal valve and the coronaries, will have a great amount of impact, as
will the type of the surgical valve.
Dr Bapat. I think what I must point out, Dr Kappetein, is that
these are a very high-risk select group of patients that have under-
gone the VIV procedure. Fit patients whowere at medium risk and,
relatively, even at high risk, have undergone open surgery.
Dr Hans-Joachim Sch€afers (Homburg/Saar, Germany).
Perhaps just 1 quick question from me and a short answer.rdiovascular Surgery c Volume 148, Number 3 923
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DThe youngest patient in your group was 43 years old. Given the
known uncertainty about the durability of these transcatheter
valves, what should be the lowest age at which we would seriously
consider transcatheter replacement?
Dr Bapat. I think you should consider, for example, in a young
woman who wants to have children, and she does not want to take924 The Journal of Thoracic and Cardiovascular Surganticoagulation. I would implant a transcatheter valve, let her
complete her family, and then reoperate.
Dr Sch€afers.Otherwise? That is a special situation. Otherwise?
Dr Bapat. If we think that the life expectancy of the patient will
be less than the durability of the transcatheter valve, we would
implant a transcatheter valve even in younger patients.ery c September 2014
